Skip to main content
Premium Trial:

Request an Annual Quote

Singulex, Qiagen Partner on Companion Dx Development

NEW YORK (360Dx) – Immunodiagnostics firm Singulex announced today that it has formed a strategic collaboration with Qiagen to develop companion diagnostics.

Under the terms of the deal, Qiagen will combine Singulex's single-molecule counting (SMC) technology with its own molecular testing services to develop companion diagnostics. Qiagen will also have access to Singulex's CLIA lab. The companies aim to collaborate in a range of disease applications, Singulex said.

Additional terms were not disclosed.

"[T]his strategic partnership is another proof point for the versatility of Singulex's high-sensitivity SMC technology," Singulex President and CEO Guido Baechler said in a statement.

The SMC technology involves combining a biological sample with paramagnetic microparticles coated with capture antibodies and detection antibodies labeled with fluorescent dye, according to Singulex. Following incubation, the microparticles are washed and processed, leaving an eluate that is separated from the microparticles and analyzed for analytes of interest.

The SMC technology is currently available only through Singulex's CLIA lab, but the company is currently developing an automated in vitro diagnostic platform — called the Clarity system — that will incorporate it.